medi-cal no longer covering glp-1 Opinion: drugs aren't just cosmetic; must cover them Health advocates are raising concerns

The hippocampus helps answer where am I? and when is this happening? The lateral septum seems to add another layer: what is rewarding here? That matters for craving

Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is characterized by hepatic steatosis without external causes (e.g., alcohol use, viral hepatitis, medications).[49] MASLD is associated with various metabolic disorders and has a bidirectional relationship with T2DM, with either disease predisposing to the other.[36] Current management guidance from the American Association for the Study of Liver Diseases emphasizes lifestyle modification and optimization of comorbidities (e.g., diabetes, obesity) while acknowledging only a handful of drug therapies with proven benefit, including GLP-1RAs.[50] In the phase 2 LEAN trial (n=26), liraglutide reduced steatosis, fibrosis, and histologic steatotic hepatitis in participants with non-alcoholic steatohepatitis.[13] In a larger study of participants with MASLD on semaglutide, steatotic hepatitis resolution was dose-dependent.[20] A study of 1,197 patients with metabolic dysfunction-associated steatohepatitis and fibrosis found nearly two-thirds (63.9%) had resolution of steatohepatitis without worsening fibrosis with weekly semaglutide 2.4mg, compared to only 34.25% in the placebo group.[19] In individuals without diabetes but with MASLD, a subgroup analysis of 26 MASLD studies identified that GLP-1RAs reduced hepatic steatosis while potentially improving liver enzymes.[14] While tirzepatide has been less studied for MASLD, it may reduce absolute liver fat.[5] Overall, GLP-1RAs may have use in patients with MASLD regardless of T2DM status, but their effects in patients with cirrhosis and significant fibrosis need further investigation

Frequently Asked Questions About Semaglutide vs Survodutide: GLP-1 vs Dual Agonist Compared Which is better, Semaglutide or Survodutide

Who should discuss their situation with a primary care provider before starting Omzo or any GLP-1 telehealth program: individuals with a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, or other conditions that may be contraindicated with GLP-1 receptor agonists

The guide to supplements to take with tirzepatide covers evidence-based options that complement the medication mechanism of action

Interestingly, these associations were not found between body weight loss one year after surgery and GLP-1 plasma levels under basal and in response to the meal test (Fig